Go Pro
→ Where to Put $100 Before Trump's New Tech Law Rolls Out (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$3.74
-1.3%		$4.13
$2.93
▼
$7.55
$469.26M1.493.00 million shs2.69 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.32
-2.6%		$8.13
$4.91
▼
$18.00
$528.29M0.951.73 million shs1.93 million shs
Vireo Growth Inc stock logo
VREOD
Vireo Growth
$9.95
$10.84
$8.91
▼
$24.00
$450.88M1.7814,588 shsN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.60
+1.7%		$0.56
$0.31
▼
$0.84
$145.70M1.1560,980 shs321,732 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+2.71%+1.61%-9.33%-9.33%-0.79%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+6.43%-5.21%-36.21%-39.53%-68.22%
Vireo Growth Inc stock logo
VREOD
Vireo Growth
0.00%0.00%0.00%-17.90%-42.57%
Vaxart, Inc. stock logo
VXRT
Vaxart
+9.26%+31.08%-7.81%-21.85%+65.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$3.74
-1.3%		$4.13
$2.93
▼
$7.55
$469.26M1.493.00 million shs2.69 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.32
-2.6%		$8.13
$4.91
▼
$18.00
$528.29M0.951.73 million shs1.93 million shs
Vireo Growth Inc stock logo
VREOD
Vireo Growth
$9.95
$10.84
$8.91
▼
$24.00
$450.88M1.7814,588 shsN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.60
+1.7%		$0.56
$0.31
▼
$0.84
$145.70M1.1560,980 shs321,732 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+2.71%+1.61%-9.33%-9.33%-0.79%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+6.43%-5.21%-36.21%-39.53%-68.22%
Vireo Growth Inc stock logo
VREOD
Vireo Growth
0.00%0.00%0.00%-17.90%-42.57%
Vaxart, Inc. stock logo
VXRT
Vaxart
+9.26%+31.08%-7.81%-21.85%+65.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$8.50127.58% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$28.20432.58% Upside
Vireo Growth Inc stock logo
VREOD
Vireo Growth
1.00
SellN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest VXRT, SPRY, AQST, and VREOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/9/2026
Vaxart, Inc. stock logo
VXRT
Vaxart
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/25/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$25.00 ➝ $24.00
6/5/2026
Vireo Growth Inc stock logo
VREOD
Vireo Growth
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
6/1/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/28/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$12.00 ➝ $30.00
5/15/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$44.54M10.52N/AN/A($0.28) per share-13.34
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$98.99M5.31N/AN/A$1.16 per share4.56
Vireo Growth Inc stock logo
VREOD
Vireo Growth
$268.77M1.68N/AN/A$8.73 per share1.14
Vaxart, Inc. stock logo
VXRT
Vaxart
$237.26M0.61$0.11 per share5.27$0.37 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/11/2026 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)
Vireo Growth Inc stock logo
VREOD
Vireo Growth
-$68.11M-$3.30N/A11.06N/A-23.37%-19.76%-7.15%N/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$16.33M$0.153.99N/AN/A14.51%61.43%20.07%8/6/2026 (Estimated)

Latest VXRT, SPRY, AQST, and VREOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4766N/AN/AN/A$31.33 millionN/A
8/11/2026Q2 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.10N/AN/AN/A$11.42 millionN/A
8/6/2026Q2 2026
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.12N/AN/AN/A$26.21 millionN/A
5/15/2026Q1 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million
5/13/2026Q1 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million
5/7/2026Q1 2026
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.02$0.02N/A$0.02$50.50 million$39.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Vireo Growth Inc stock logo
VREOD
Vireo Growth
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.10
3.85
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.79
4.94
4.77
Vireo Growth Inc stock logo
VREOD
Vireo Growth
0.70
1.20
0.84
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
1.71
1.71

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Vireo Growth Inc stock logo
VREOD
Vireo Growth
N/A
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
6.81%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Vireo Growth Inc stock logo
VREOD
Vireo Growth
3.80%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
160125.47 million116.92 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9099.30 million65.74 millionOptionable
Vireo Growth Inc stock logo
VREOD
Vireo Growth
50045.32 million43.59 millionNot Optionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120242.84 million236.04 millionNo Data

Recent News About These Companies

Vaxart (VXRT) Expected to Post Earnings on Thursday
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxart-vxrt-expected-to-post-earnings-on-thursday-2026-08-04/
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-host-stockholder-fireside-chat-120000165.html
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335990/25416/en/vaxart-to-host-stockholder-fireside-chat-on-august-7-at-4-30-p-m-et.html
Vaxart (OTCMKTS:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?
July 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30925641
Vaxart (OTCMKTS:VXRT) Shares Pass Below 200 Day Moving Average - What's Next?
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxart-otcmktsvxrt-shares-pass-below-200-day-moving-average-whats-next-2026-07-28/
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-participate-btig-biotechnology-conference-120000945.html
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330405/25416/en/vaxart-to-participate-in-btig-biotechnology-conference-2026.html
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxart-investors-reject-say-on-pay-as-ceo-rules-out-reverse-split-for-now-2026-07-20/
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-announces-results-annual-meeting-200500981.html
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329278/25416/en/vaxart-announces-results-of-annual-meeting-of-stockholders.html
Vaxart (OTCMKTS:VXRT) Stock Rating Upgraded by Zacks Research
July 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxart-otcmktsvxrt-stock-rating-upgraded-by-zacks-research-2026-07-11/
Vaxart (OTCMKTS:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What Happened
July 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vaxart-otcmktsvxrt-share-price-passes-below-200-day-moving-average-heres-what-happened-2026-07-10/
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
July 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-reports-topline-12-month-200100867.html
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
July 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322727/25416/en/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-safety-cohort-of-the-phase-2b-clinical-trial-of-its-oral-pill-covid-19-vaccine.html
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
July 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-enters-cooperation-agreement-stockholder-200000571.html
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320966/25416/en/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-and-corporate-governance-enhancements.html
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-company-s-highly-qualified-director-nominees-on-the-white-proxy-card-today-1036278947
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318181/25416/en/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-company-s-highly-qualified-director-nominees-on-the-white-proxy-card-today.html
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
June 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-announces-barda-funding-award-120000156.html
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317471/25416/en/vaxart-announces-update-to-barda-funding-award-to-reflect-current-scope-of-covid-19-oral-pill-vaccine-trial.html
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
June 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-two-newest-independent-directors-120000243.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$3.74 -0.05 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$3.78 +0.04 (+1.20%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$5.32 -0.14 (-2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$5.35 +0.03 (+0.64%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Vireo Growth stock logo

Vireo Growth OTCMKTS:VREOD

$9.95 0.00 (0.00%)
As of 08/3/2026

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.

Vaxart stock logo

Vaxart OTCMKTS:VXRT

$0.60 +0.01 (+1.69%)
As of 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas